Trials / Completed
CompletedNCT00434148
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pasireotide |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-03-01
- Completion
- 2014-05-01
- First posted
- 2007-02-12
- Last updated
- 2016-03-08
- Results posted
- 2013-02-06
Locations
68 sites across 18 countries: United States, Argentina, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Poland, Portugal, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00434148. Inclusion in this directory is not an endorsement.